{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:02:33Z","timestamp":1794272553731,"version":"4.9.0"},"reference-count":32,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.31744\/einstein_journal\/2026ao1668","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:11:40Z","timestamp":1783005100000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of anticoagulation quality in patients with primary antiphospholipid syndrome at a tertiary hospital"],"prefix":"10.31744","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0120-2251","authenticated-orcid":false,"given":"Renata Lys Pinheiro de","family":"Mello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0713-6790","authenticated-orcid":false,"given":"Maria Eug\u00eania Teixeira","family":"Bicalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0235-8834","authenticated-orcid":false,"given":"Gustavo Guimar\u00e3es Moreira","family":"Balbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1017","authenticated-orcid":false,"given":"Flavio","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-1808","authenticated-orcid":false,"given":"Danieli Castro Oliveira de","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"10","key":"key20260702131450_B1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","unstructured":"1 Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesus G, Delluc A, Desai S, De Sancho M, Devreese KM, Diz-Kucukkaya R, Duarte-Garcia A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR\/EULAR APS Classification Criteria Collaborators. The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol. 2023;75(10):1687-702.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"key20260702131450_B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","unstructured":"2 Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ram\u00f3n E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Qu\u00e9r\u00e9 I, Hachulla E, Vasconcelos C, Fern\u00e1ndez-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011-8.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"key20260702131450_B3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi","year":"2017","unstructured":"3 Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31(6):406-17.","journal-title":"Blood Rev"},{"issue":"10","key":"key20260702131450_B4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","unstructured":"4 Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"key20260702131450_B5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000924","article-title":"Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","unstructured":"5 Tektonidou MG, Andreoli L, Limper M, Tincani A, Ward MM. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open. 2019;5(1):e000924.","journal-title":"RMD Open"},{"issue":"9","key":"key20260702131450_B6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jama.295.9.1050","article-title":"Management of antiphospholipid antibody syndrome: a systematic review","volume":"295","author":"Lim","year":"2006","unstructured":"6 Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295(9):1050-7.","journal-title":"JAMA"},{"issue":"6","key":"key20260702131450_B7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00228-019-02655-8","article-title":"Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data","volume":"75","author":"Xue","year":"2019","unstructured":"7 Xue L, Zhang Y, Xie C, Zhou L, Liu L, Zhang H, et al. Relationship between warfarin dosage and international normalized ratio: a dose-response analysis and evaluation based on multicenter data. Eur J Clin Pharmacol. 2019;75(6):785-94.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"key20260702131450_B8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cpt.668","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update","volume":"102","author":"Johnson","year":"2017","unstructured":"8 Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"key20260702131450_B9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data","volume":"360","author":"Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data","year":"2009","unstructured":"9 Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N Engl J Med. 2009;360(8):753-64.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20260702131450_B10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","article-title":"Drug and dietary interactions of warfarin and novel oral anticoagulants: an update","volume":"31","author":"Nutescu","year":"2011","unstructured":"10 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326-43.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"key20260702131450_B11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11239-011-0555-z","article-title":"Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure","volume":"31","author":"Lee","year":"2011","unstructured":"11 Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis. 2011;31(3):249-58.","journal-title":"J Thromb Thrombolysis"},{"issue":"1110","key":"key20260702131450_B12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/postgradmedj-2017-135457","article-title":"Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin","volume":"94","author":"Huang","year":"2018","unstructured":"12 Huang D, Wong CL, Cheng KW, Chan PH, Yue WS, Wong CK, et al. Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin. Postgrad Med J. 2018;94(1110):207-11.","journal-title":"Postgrad Med J"},{"issue":"5","key":"key20260702131450_B13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5603\/CJ.a2015.0035","article-title":"Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry","volume":"22","author":"Turk","year":"2015","unstructured":"13 Turk UO, Tuncer E, Alioglu E, Yuksel K, Pekel N, Ozpelit E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry. Cardiol J. 2015;22(5):567-75.","journal-title":"Cardiol J"},{"key":"key20260702131450_B14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2015.03.017","article-title":"Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry","volume":"170","author":"Pokorney","year":"2015","unstructured":"14 Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al. Patients\u2019 time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015;170:141-8.e1.","journal-title":"Am Heart J"},{"issue":"3","key":"key20260702131450_B15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","unstructured":"15 Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236-9.","journal-title":"Thromb Haemost"},{"issue":"3","key":"key20260702131450_B16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","unstructured":"16 White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-45.","journal-title":"Arch Intern Med"},{"issue":"10","key":"key20260702131450_B17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis","volume":"174","author":"Khan","year":"2021","unstructured":"17 Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, B\u00fcller HR, Raskob GE, Ageno W, Couturaud F, Prandoni P, Palareti G, Legnani C, Kyrle PA, Eichinger S, Eischer L, Becattini C, Agnelli G, Vedovati MC, Geersing GJ, Takada T, Cosmi B, Aujesky D, Marconi L, Palla A, Siragusa S, Bradbury CA, Parpia S, Mallick R, Lensing AWA, Gebel M, Grosso MA, Thavorn K, Hutton B, Le Gal G, Fergusson DA, Rodger MA; MAJESTIC Collaborators. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis. Ann Intern Med. 2021;174(10):1420-9.","journal-title":"Ann Intern Med"},{"issue":"3","key":"key20260702131450_B18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/03007995.2017.1384370","article-title":"Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation","volume":"34","author":"Liu","year":"2018","unstructured":"18 Liu S, Li X, Shi Q, Hamilton M, Friend K, Zhao Y, et al. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation. Curr Med Res Opin. 2018;34(3):415-21.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"key20260702131450_B19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016980","article-title":"Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada","volume":"8","author":"McAlister","year":"2018","unstructured":"19 McAlister FA, Wiebe N, Hemmelgarn BR. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada. BMJ Open. 2018;8(1):e016980.","journal-title":"BMJ Open"},{"issue":"3","key":"key20260702131450_B20","first-page":"457","article-title":"Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study","volume":"114","author":"Silva","year":"2020","unstructured":"20 Silva PG, Sznejder H, Vasconcellos R, Charles GM, Mendonca-Filho HT, Mardekian J, et al. Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study. Arq Bras Cardiol. 2020;114(3):457-66.","journal-title":"Arq Bras Cardiol"},{"issue":"11","key":"key20260702131450_B21","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","unstructured":"21 Devreese KM, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18(11):2828-39.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"key20260702131450_B22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/00313020310001643615","article-title":"Consensus guidelines on anti-cardiolipin antibody testing and reporting","volume":"36","author":"Wong","year":"2004","unstructured":"22 Wong RC, Gillis D, Adelstein S, Baumgart K, Favaloro EJ, Hendle MJ, et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology. 2004;36(1):63-8.","journal-title":"Pathology"},{"issue":"9","key":"key20260702131450_B23","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1177\/0961203318776105","article-title":"Revisiting the Phadia\/EliA cut-off values for anticardiolipin and anti-\u03b22-glycoprotein I antibodies: a systematic evaluation according to the guidelines","volume":"27","author":"Bor","year":"2018","unstructured":"23 Bor MV, Jacobsen IS, Gram JB, Sidelmann JJ. Revisiting the Phadia\/EliA cut-off values for anticardiolipin and anti-\u03b22-glycoprotein I antibodies: a systematic evaluation according to the guidelines. Lupus. 2018;27(9):1446-54.","journal-title":"Lupus"},{"issue":"3","key":"key20260702131450_B24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort","volume":"49","author":"Radin","year":"2019","unstructured":"24 Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jes\u00fas G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Semin Arthritis Rheum. 2019;49(3):464-8.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"key20260702131450_B25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/1744666X.2019.1543025","article-title":"Clinical profiles and risk assessment in patients with antiphospholipid antibodies","volume":"15","author":"Kato","year":"2019","unstructured":"25 Kato M, Hisada R, Atsumi T. Clinical profiles and risk assessment in patients with antiphospholipid antibodies. Expert Rev Clin Immunol. 2019;15(1):73-81.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"key20260702131450_B26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","unstructured":"26 Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-4.","journal-title":"J Thromb Haemost"},{"issue":"17","key":"key20260702131450_B27","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"Pengo","year":"2011","unstructured":"27 Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714-8.","journal-title":"Blood"},{"key":"key20260702131450_B28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2015.10.105","article-title":"Antiphospholipid syndrome and anticoagulation quality: a clinical challenge","volume":"244","author":"Pastori","year":"2016","unstructured":"28 Pastori D, Parrotto S, Vicario T, Saliola M, Mezzaroma I, Violi F, et al. Antiphospholipid syndrome and anticoagulation quality: a clinical challenge. Atherosclerosis. 2016;244:48-50.","journal-title":"Atherosclerosis"},{"key":"key20260702131450_B29","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/j.rbr.2017.07.484","article-title":"Evaluation of Anticoagulation Monitoring in Patients with Antiphospholipid Syndrome (APS) and Its Correlation with Clinical Outcomes","volume":"57","author":"Balbi","year":"2017","unstructured":"29 Balbi GG, Signorelli F, Vieira M, Verztman VR, Nogueira F, Levy RA. Evaluation of Anticoagulation Monitoring in Patients with Antiphospholipid Syndrome (APS) and Its Correlation with Clinical Outcomes. Rev Bras Reumatol. 2017;57:S350-1.","journal-title":"Rev Bras Reumatol"},{"issue":"2","key":"key20260702131450_B30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.amjmed.2024.09.019","article-title":"Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes","volume":"138","author":"Meir","year":"2025","unstructured":"30 Meir K, Niznik S, Avnery O, Zoref-Lorenz A, Agmon-Levin N, Ellis MH. Vitamin K Antagonist Anticoagulation in Antiphospholipid Syndrome: Time in Therapeutic Range and Clinical Outcomes. Am J Med. 2025;138(2):269-76.e1.","journal-title":"Am J Med"},{"issue":"2","key":"key20260702131450_B31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2009.07.020","article-title":"Fibrate\/Statin initiation in warfarin users and gastrointestinal bleeding risk","volume":"123","author":"Schelleman","year":"2010","unstructured":"31 Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate\/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med. 2010;123(2):151-7.","journal-title":"Am J Med"},{"issue":"2","key":"key20260702131450_B32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS Action International Clinical Database and Repository","volume":"74","author":"Sevim","year":"2022","unstructured":"32 Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, Ugarte A, Gerosa M, Belmont HM, Zamorano MAA, Fortin PR, Ji L, Efthymiou M, Cohen H, Branch DW, de Jesus GR, Andreoli L, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Roubey R, Bertolaccini ML, Erkan D, Barbhaiya M; APS ACTION Investigators. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS Action International Clinical Database and Repository. Arthritis Care Res (Hoboken). 2022;74(2):324-35.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:11:44Z","timestamp":1783005104000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/evaluation-of-anticoagulation-quality-in-patients-with-primary-antiphospholipid-syndrome-at-a-tertiary-hospital\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"alternative-id":["10.31744\/einstein_journal\/2026AO1668"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2026ao1668","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"eAO1668"}}